Alpha 2.0
Login Register
» Authors » Pierfederico Torchio

Pierfederico Torchio

Explore the profile of Pierfederico Torchio including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 229
Followers 0
Related Specialties
General Surgery
Hematology
Cardiology & Vascular Diseases
Top 10 Co-Authors
Marco Agostini
Domenico Ferrigno
Gianfranco Buccheri
Claudio Grossi
Luigi Rigacci
Alessandro Levis
Carlo Fino
Elisa Lugli
Emilio Iannitto
Marco Bertora
Published In
Cancer
Blood
Hum Vaccin Immunother
Chest
J Card Surg
Affiliations
Soon will be listed here.
Recent Articles
1.
Attributes influencing parental decision-making to receive the Tdap vaccine to reduce the risk of pertussis transmission to their newborn - outcome of a cross-sectional conjoint experiment in Spain and Italy
Ledent E, Gabutti G, de Bekker-Grob E, Alcazar Zambrano J, Campins Marti M, Del Hierro Gurruchaga M, et al.
Hum Vaccin Immunother . 2019 Feb; 15(5):1080-1091. PMID: 30735474
Pertussis vaccination of parents and household contacts ('cocooning') to protect newborn infants is an established strategy in many countries, although uptake may be low. Many aspects may influence such decision-making....
2.
High OPCAB surgical volume improves midterm event-free survival
Agostini M, Fino C, Torchio P, di Gregorio V, Feola M, Bertora M, et al.
Heart Surg Forum . 2009 Oct; 12(5):E250-5. PMID: 19833590
Background: The aim of this study was to evaluate the midterm results of the initial phase of off-pump coronary artery bypass (OPCAB) surgery adoption in a single surgical unit, assessing...
3.
Impact of incomplete revascularization following OPCAB surgery
Agostini M, Fino C, Torchio P, Vado A, Bertora M, Lugli E, et al.
J Card Surg . 2009 Sep; 24(6):650-6. PMID: 19732224
Background And Aim Of The Study: The aim of this study was to evaluate the early and mid-term off-pump coronary artery bypass surgery (OPCAB) results in a single surgical unit,...
4.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Gallamini A, Zaja F, Patti C, Billio A, Specchia M, Tucci A, et al.
Blood . 2007 Jun; 110(7):2316-23. PMID: 17581918
To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients...
5.
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al.
Haematologica . 2006 Apr; 91(4):475-81. PMID: 16585014
Background And Objectives: We explored the predictive value on therapy outcome of an early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomography (18F-FDG-PET) scan performed after two courses of...
6.
Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments
Buccheri G, Torchio P, Ferrigno D
Chest . 2003 Aug; 124(2):622-32. PMID: 12907552
Study Objectives: We have longstanding experience with tissue polypeptide antigen (TPA), a tumor marker of the cytokeratin (CK) family. In the mid-1990s, a new CK marker, CK 19 fragments (CYFRA...
7.
Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance
Buccheri G, Torchio P, Ferrigno D
Cancer . 2003 Jun; 97(12):3044-52. PMID: 12784340
Background: The activation of the clotting-fibrinolytic system in cancer patients is common and represents an unfavorable clinical sign. D-dimer (DD) is a sensitive marker of fibrinolysis. Methods: The current study...